Kynexis will now prepare for registrational studies on lead asset, KYN-5356 in cognitive impairment associated with schizophrenia (CIAS).

Ultragenyx Pharmaceutical has received accelerated approval from the FDA for its gene therapy, Genglycos, to treat GSDIa.

Analysts say that ALE1’s combination of oral administration and differentiated biology could put it in an advantageous position. Credit: eamesBot/Shutterstock.com. BioMarin Pharmaceutical has outlaid ...

To become FDA commissioner, Overton would have to be sworn in by the Senate. Credit: mark reinstein / Shutterstock.com. US President Donald Trump is expected to put forward Heidi Overton as his choice ...

Andelyn Biosciences is set to develop and manufacture a gene therapy known as AAV9-GM2, for Queen’s University to treat GM2 gangliosidoses, including Tay-Sachs and Sandhoff diseases.

BeOne Medicines, the BeOne Care Foundation, and The Max Foundation have extended their Brukinsa access programme for CLL until 2028.

Tanabe’s dersimelagon is already under FDA review having achieved positive Phase III results earlier this year.

Faeth Therapeutics has received fast track designation from the FDA for the PIKTOR with paclitaxel combination to treat advanced or recurrent endometrial cancer.

Fulcrum Therapeutics and Slate Medicines have signed a definitive agreement to merge in an all-stock transaction backed by a $245m private placement financing from a syndicate of healthcare investors.

Discover how GSK, Boehringer Ingelheim, Takeda and more than 100 pharma leaders scale digital projects at AUTOMA+ 2026 in Switzerland.

Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.

Lantheus's radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) pathology.